Hai Ning Wee1, Jian-Jun Liu2, Jianhong Ching3,4, Jean-Paul Kovalik3, Su Chi Lim2,5,6. 1. Duke-NUS Medical School, Singapore, Singapore, haining.wee@duke-nus.edu.sg. 2. Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore. 3. Duke-NUS Medical School, Singapore, Singapore. 4. KK Research Centre, KK Women's and Children's Hospital, Singapore, Singapore. 5. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 6. Diabetes Centre, Admiralty Medical Centre, Singapore, Singapore.
Abstract
BACKGROUND: The kynurenine pathway (KP) is the major catabolic pathway for tryptophan degradation. The KP plays an important role as the sole de novo nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway in normal human physiology and functions as a counter-regulatory mechanism to mitigate immune responses during inflammation. Although the KP has been implicated in a variety of disorders including Huntington's disease, seizures, cardiovascular disease, and osteoporosis, its role in renal diseases is seldom discussed. SUMMARY: This review summarizes the roles of the KP and its metabolites in acute kidney injury (AKI) and chronic kidney disease (CKD) based on current literature evidence. Metabolomics studies demonstrated that the KP metabolites were significantly altered in patients and animal models with AKI or CKD. The diagnostic and prognostic values of the KP metabolites in AKI and CKD were highlighted in cross-sectional and longitudinal human observational studies. The biological impact of the KP on the pathophysiology of AKI and CKD has been studied in experimental models of different etiologies. In particular, the activation of the KP was found to confer protection in animal models of glomerulonephritis, and its immunomodulatory mechanism may involve the regulation of T cell subsets such as Th17 and regulatory T cells. Manipulation of the KP to increase NAD+ production or diversion toward specific KP metabolites was also found to be beneficial in animal models of AKI. Key Messages: KP metabolites are reported to be dysregulated in human observational and animal experimental studies of AKI and CKD. In AKI, the magnitude and direction of changes in the KP depend on the etiology of the damage. In CKD, KP metabolites are altered with the onset and progression of CKD all the way to advanced stages of the disease, including uremia and its related vascular complications. The activation of the KP and diversion to specific sub-branches are currently being explored as therapeutic strategies in these diseases, especially with regards to the immunomodulatory effects of certain KP metabolites. Further elucidation of the KP may hold promise for the development of biomarkers and targeted therapies for these kidney diseases.
BACKGROUND: The kynurenine pathway (KP) is the major catabolic pathway for tryptophan degradation. The KP plays an important role as the sole de novo nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway in normal human physiology and functions as a counter-regulatory mechanism to mitigate immune responses during inflammation. Although the KP has been implicated in a variety of disorders including Huntington's disease, seizures, cardiovascular disease, and osteoporosis, its role in renal diseases is seldom discussed. SUMMARY: This review summarizes the roles of the KP and its metabolites in acute kidney injury (AKI) and chronic kidney disease (CKD) based on current literature evidence. Metabolomics studies demonstrated that the KP metabolites were significantly altered in patients and animal models with AKI or CKD. The diagnostic and prognostic values of the KP metabolites in AKI and CKD were highlighted in cross-sectional and longitudinal human observational studies. The biological impact of the KP on the pathophysiology of AKI and CKD has been studied in experimental models of different etiologies. In particular, the activation of the KP was found to confer protection in animal models of glomerulonephritis, and its immunomodulatory mechanism may involve the regulation of T cell subsets such as Th17 and regulatory T cells. Manipulation of the KP to increase NAD+ production or diversion toward specific KP metabolites was also found to be beneficial in animal models of AKI. Key Messages: KP metabolites are reported to be dysregulated in human observational and animal experimental studies of AKI and CKD. In AKI, the magnitude and direction of changes in the KP depend on the etiology of the damage. In CKD, KP metabolites are altered with the onset and progression of CKD all the way to advanced stages of the disease, including uremia and its related vascular complications. The activation of the KP and diversion to specific sub-branches are currently being explored as therapeutic strategies in these diseases, especially with regards to the immunomodulatory effects of certain KP metabolites. Further elucidation of the KP may hold promise for the development of biomarkers and targeted therapies for these kidney diseases.
Authors: Natarajan Ranganathan; Pari Ranganathan; Eli A Friedman; Anthony Joseph; Barbara Delano; David S Goldfarb; Paul Tam; A Venketeshwer Rao; Emmanuel Anteyi; Carlos Guido Musso Journal: Adv Ther Date: 2010-08-16 Impact factor: 3.845
Authors: Konstantinos A Polyzos; Olga Ovchinnikova; Martin Berg; Roland Baumgartner; Hanna Agardh; John Pirault; Anton Gisterå; Alice Assinger; Andres Laguna-Fernandez; Magnus Bäck; Göran K Hansson; Daniel F J Ketelhuth Journal: Cardiovasc Res Date: 2015-03-05 Impact factor: 10.787
Authors: Maria L Belladonna; Ursula Grohmann; Paolo Guidetti; Claudia Volpi; Roberta Bianchi; Maria C Fioretti; Robert Schwarcz; Francesca Fallarino; Paolo Puccetti Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Eugene P Rhee; Amanda Souza; Laurie Farrell; Martin R Pollak; Gregory D Lewis; David J R Steele; Ravi Thadhani; Clary B Clish; Anna Greka; Robert E Gerszten Journal: J Am Soc Nephrol Date: 2010-04-08 Impact factor: 10.121
Authors: Mina H Hanna; Jeffrey L Segar; Lynn M Teesch; David C Kasper; Franz S Schaefer; Patrick D Brophy Journal: Pediatr Res Date: 2013-02-14 Impact factor: 3.756
Authors: Jesse A Davidson; Justin Robison; Ludmila Khailova; Benjamin S Frank; James Jaggers; Richard J Ing; Scott Lawson; John Iguidbashian; Eiman Ali; Amy Treece; Danielle E Soranno; Suzanne Osorio-Lujan; Jelena Klawitter Journal: Am J Physiol Renal Physiol Date: 2022-05-09
Authors: Laiba Jamshed; Amrita Debnath; Shanza Jamshed; Jade V Wish; Jason C Raine; Gregg T Tomy; Philippe J Thomas; Alison C Holloway Journal: Int J Mol Sci Date: 2022-06-04 Impact factor: 6.208